JP2018513216A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513216A5 JP2018513216A5 JP2018505578A JP2018505578A JP2018513216A5 JP 2018513216 A5 JP2018513216 A5 JP 2018513216A5 JP 2018505578 A JP2018505578 A JP 2018505578A JP 2018505578 A JP2018505578 A JP 2018505578A JP 2018513216 A5 JP2018513216 A5 JP 2018513216A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- medicine
- antigen receptor
- cells
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 22
- 210000004027 cell Anatomy 0.000 claims 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- 238000002347 injection Methods 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 4
- 210000002767 hepatic artery Anatomy 0.000 claims 4
- 210000004185 liver Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 238000002583 angiography Methods 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000000004 hemodynamic effect Effects 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000036449 good health Effects 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562147793P | 2015-04-15 | 2015-04-15 | |
| US62/147,793 | 2015-04-15 | ||
| PCT/US2016/027582 WO2016168493A1 (en) | 2015-04-15 | 2016-04-14 | Hepatic arterial infusion of car-t cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018513216A JP2018513216A (ja) | 2018-05-24 |
| JP2018513216A5 true JP2018513216A5 (OSRAM) | 2019-05-23 |
Family
ID=57126310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505578A Pending JP2018513216A (ja) | 2015-04-15 | 2016-04-14 | Ｃａｒ−ｔ細胞の肝動脈注入 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10471098B2 (OSRAM) |
| EP (1) | EP3283083A4 (OSRAM) |
| JP (1) | JP2018513216A (OSRAM) |
| KR (1) | KR20180021364A (OSRAM) |
| CN (1) | CN108135937A (OSRAM) |
| AR (1) | AR104296A1 (OSRAM) |
| AU (1) | AU2016248090A1 (OSRAM) |
| CA (1) | CA2982603A1 (OSRAM) |
| HK (1) | HK1251179A1 (OSRAM) |
| IL (1) | IL255005A0 (OSRAM) |
| MX (1) | MX2017013247A (OSRAM) |
| TW (1) | TWI719019B (OSRAM) |
| WO (1) | WO2016168493A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2948135T3 (es) | 2015-06-24 | 2023-08-31 | Univ Michigan Regents | Sistemas de terapia de histotripsia para el tratamiento del tejido cerebral |
| CN107056952A (zh) * | 2017-05-10 | 2017-08-18 | 常州市第人民医院 | Cea.car‑t及其制备与应用 |
| US20200215112A1 (en) * | 2017-08-09 | 2020-07-09 | Ctg Pharma Ltd. | Chimeric antigen receptor for her2/neu and t-cells expressing same |
| CA3080109A1 (en) * | 2017-11-03 | 2019-05-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
| JP7355294B2 (ja) * | 2017-11-30 | 2023-10-03 | シンガポール ヘルス サービシズ ピーティーイー． リミテッド | がん患者を適切ながん処置群に分類するためのシステム及び方法、並びに患者を処置するための化合物 |
| AU2019231315A1 (en) * | 2018-03-09 | 2020-09-17 | Vivasor, Inc. | Dimeric antigen receptors (DAR) |
| AU2019311077B2 (en) * | 2018-07-23 | 2025-05-29 | Heidelberg Pharma Research Gmbh | Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy |
| SG11202101014XA (en) * | 2018-08-02 | 2021-02-25 | Kite Pharma Inc | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
| US20210346430A9 (en) * | 2018-08-26 | 2021-11-11 | Oaiscell Biotechnologies | Method for treating glioblastoma |
| JP7520818B2 (ja) * | 2018-09-13 | 2024-07-23 | ンカルタ・インコーポレイテッド | 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法 |
| CN120324803A (zh) | 2018-11-28 | 2025-07-18 | 希斯托索尼克斯公司 | 组织摧毁术系统及方法 |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| EP3799881A1 (en) | 2019-10-04 | 2021-04-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Single domain antibodies specifically binding globo - series glycans |
| MX2022006288A (es) * | 2019-11-25 | 2022-06-08 | Univ Kyoto | Banco de celulas maestras de celulas t. |
| EP4096782A4 (en) * | 2020-01-28 | 2024-02-14 | The Regents Of The University Of Michigan | SYSTEMS AND METHODS FOR HISTOTRIPSIA IMMUNOSENSITIZATION |
| AU2021332372A1 (en) | 2020-08-27 | 2023-03-16 | The Regents Of The University Of Michigan | Ultrasound transducer with transmit-receive capability for histotripsy |
| CN116685330A (zh) * | 2020-09-22 | 2023-09-01 | 特萨乐斯生命科学公司 | 使用toll样受体激动剂的癌症疗法 |
| US20230364125A1 (en) * | 2020-09-22 | 2023-11-16 | Trisalus Life Sciences, Inc. | Cancer therapy using toll-like receptor agonists |
| US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
| CA3204922A1 (en) * | 2021-02-09 | 2022-08-18 | Ming-Tain Lai | Globo series antigens-binding chimeric antigen receptors and uses thereof |
| EP4608504A1 (en) | 2022-10-28 | 2025-09-03 | Histosonics, Inc. | Histotripsy systems and methods |
| AU2024257180A1 (en) | 2023-04-20 | 2025-09-18 | Histosonics, Inc. | Histotripsy systems and associated methods including user interfaces and workflows for treatment planning and therapy |
| WO2025144964A2 (en) * | 2023-12-29 | 2025-07-03 | AffyImmune Therapeutics Inc. | Novel car constructs and methods of treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US20020165360A1 (en) * | 2000-11-30 | 2002-11-07 | Junghans Richard P. | Chimeric effector cell receptors against carcinoembryonic antigen |
| WO2010085660A2 (en) | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| CN110200997A (zh) * | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| CN104853766A (zh) * | 2012-10-02 | 2015-08-19 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| MY175869A (en) | 2013-02-26 | 2020-07-14 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
-
2016
- 2016-04-14 TW TW105111666A patent/TWI719019B/zh not_active IP Right Cessation
- 2016-04-14 WO PCT/US2016/027582 patent/WO2016168493A1/en not_active Ceased
- 2016-04-14 US US15/099,370 patent/US10471098B2/en not_active Expired - Fee Related
- 2016-04-14 AU AU2016248090A patent/AU2016248090A1/en not_active Abandoned
- 2016-04-14 CA CA2982603A patent/CA2982603A1/en not_active Abandoned
- 2016-04-14 HK HK18110746.6A patent/HK1251179A1/zh unknown
- 2016-04-14 EP EP16780765.0A patent/EP3283083A4/en not_active Withdrawn
- 2016-04-14 KR KR1020177033070A patent/KR20180021364A/ko not_active Withdrawn
- 2016-04-14 MX MX2017013247A patent/MX2017013247A/es unknown
- 2016-04-14 CN CN201680035380.XA patent/CN108135937A/zh active Pending
- 2016-04-14 JP JP2018505578A patent/JP2018513216A/ja active Pending
- 2016-04-15 AR ARP160101045A patent/AR104296A1/es unknown
-
2017
- 2017-10-15 IL IL255005A patent/IL255005A0/en unknown
-
2019
- 2019-10-09 US US16/597,798 patent/US20200138863A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513216A5 (OSRAM) | ||
| CN113286879B (zh) | 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子 | |
| Harrer et al. | RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma | |
| ES2734190T3 (es) | Receptores de linfocitos T | |
| Slaney et al. | Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting | |
| JP2017507917A5 (OSRAM) | ||
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| EP2990416B1 (en) | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
| Ma et al. | Advanced generation anti‐prostate specific membrane antigen designer T Cells for prostate cancer immunotherapy | |
| JP2017509342A5 (OSRAM) | ||
| AU2025205213A1 (en) | Chimeric antigen receptor T cells targeting the tumor microenvironment | |
| JP2017537622A5 (OSRAM) | ||
| JP2019500894A5 (OSRAM) | ||
| JP2019519215A5 (OSRAM) | ||
| JP2018509163A5 (OSRAM) | ||
| JP2017537627A5 (OSRAM) | ||
| Wang et al. | What happens to the immune microenvironment after PD-1 inhibitor therapy? | |
| RU2017102769A (ru) | EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА | |
| JP2017507936A5 (OSRAM) | ||
| JP2016520074A5 (OSRAM) | ||
| JP2018502060A5 (OSRAM) | ||
| JP2016519933A5 (OSRAM) | ||
| JP2020517658A5 (OSRAM) | ||
| RU2016143155A (ru) | Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака | |
| JP2018520094A5 (OSRAM) |